June 9, 2016—ArcherDx has announced two agreements related to its work in next-generation sequencing.
Under terms of an agreement with Illumina, ArcherDx will lead the development of a series of diagnostic tests utilizing ArcherDx’s Anchored Multiplex PCR chemistry that will be run on the Illumina MiSeqDx instrument. This agreement reflects the commitment of both companies to provide NGS-based diagnostics to support current and future clinical trials.
“The Archer-Illumina partnership enables our vision of creating a companion test aligned to the current and next generations of targeted therapies, rather than a single companion diagnostic targeting a single targeted therapy. This will dramatically improve patient outcomes and lower the sample and cost burdens of clinical sequencing in the future,” ArcherDx CEO Jason Myers, PhD, said in a statement. “This approach is a paradigm shift from the ‘one test for one drug’ method.”
ArcherDx, headquartered in Boulder, Colo., said it aims to address the bottlenecks associated with using NGS in translational research by offering a platform for targeted sequencing applications.
In a separate announcement, the company said Cancer Genetics Inc. will provide its Archer FusionPlex NGS assays. CGI also plans to use Archer VariantPlex assays to identify copy number variants and point mutations in tumor samples and will be testing these assays in cell-free variant detection. With headquarters in New Jersey and locations in North Carolina, California, India, and China, CGI supports biopharma with genomics-based, comprehensive biomarker assessment technologies and services, including markers for immuno-oncology.